Table 3 Mean level of PTEN methylation status among clinicopathological factors
From: Clinical impact of PTEN methylation status as a prognostic marker for breast cancer
Characters | PTEN methylation status |
|---|---|
Mean ± SEM | |
Age | |
 ≤ 50 years | 84 ± 1.8 |
 > 50 years | 71.7 ± 2.6 |
|  | F = 14.9, P < 0.001 |
Menopausal status | |
 Pre-menopause | 83.7 |
 Post-menopause | 68.9 |
|  | F = 21.9, P < 0.001 |
Pathological type | |
 DCI | 66.5 |
 IDC | 86.1 |
|  | F = 46.5, P < 0.001 |
Clinical stage | |
 Early stage | 67.7 |
 Late stage | 85.8 |
|  | F = 46.5, P < 0.001 |
Histological grade | |
 Low grade | 67.7 |
 High grade | 84.4 |
|  | F = 32.5, P < 0.001 |
Lymph node involvement | |
 Negative | 71.5 |
 Positive | 85.5 |
|  | F = 20.3, P < 0.001 |
ER status | |
 Negative (n) | 73.7 |
 Positive (n) | 82.7 |
| Â | F = 7.5, P = 0.007 |
PgR status | |
 Negative (n) | 72.9 |
 Positive (n) | 80.8 |
| Â | F = 5.3, P = 0.023 |
HER-2neu status | |
 Negative (n) | 70.8 |
 Positive (n) | 82 |
| Â | F = 11.3, P = 0.001 |